- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01769235
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
May 3, 2017 updated by: Taro Pharmaceuticals USA
A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Gel, 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% and to demonstrate the superior efficacy of the two active formulations over that of the vehicle in the treatment of acne vulgaris.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
1215
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 40 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be willing and able to provide written informed consent/assent for the study.
- Be 12 to 40 years of age, inclusive. A subject may be of either sex and any race/ethnicity.
- Have a clinical diagnosis of facial acne vulgaris with 25 or greater non-inflammatory lesions and 20 or greater inflammatory lesions and no more than 2 nodulocystic lesions.
- Have a baseline Investigator's Global Assessment of acne severity grade of 2, 3 or 4 on a severity scale of 0 to 4.
- Be willing and able to understand and comply with the requirements of the study, apply the study medication as instructed, refrain from use of all other topical acne medication and topical antibiotics during the 12-week treatment period, return for the required treatment period visits, comply with therapy prohibitions, and able to complete the study.
- Be in general good health and free from any clinically significant disease, other than acne vulgaris, that might interfere with the study evaluations.
- Female subjects of childbearing potential must have a negative urine pregnancy test amd must be willing to use a medically accepted method of contraception during the study.
Exclusion Criteria:
- Presence of more than 2 facial nodulocystic lesions (i.e., nodules and cysts).
- Current diagnosis of acne conglobata, acne fulminans, or secondary acne.
- Presence of active cystic acne, or polycystic ovarian syndrome.
- History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis.
- Presence of any other facial skin condition that might interfere with acne vulgaris diagnosis and/or assessment.
- Excessive facial hair that would interfere with diagnosis or assessment of acne vulgaris.
- History of unresponsiveness to topical clindamycin phosphate and/or benzoyl peroxide therapy.
- Start or change of dose of estrogens or hormonal treatment 3 months prior to baseline or throughout the study.
- Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days of study entry and throughout the study.
- Use of any of the following treatments more recently than the indicated washout period prior to visit 1/day 1; need or intent to continue to use any of the following treatments during the study: oral retinoids or therapeutic Vitamin A supplements of greater than 10,000 units/day; systemic steroids; systemic antibiotics; systemic treatment for acne vulgaris ; systemic anti-inflammatory or immunosuppressive agents (NSAID use is allowed on an as-needed basis but for no more than 7 days of consecutive use, low dose aspirin is allowed if on a stable dose for at least 30 days); Spironolactone; use on the face of cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, x-ray therapy; topical retinoids; topical steroids; topical anti-acne medications; topical anti-inflammatory agents; topical antibiotics; medicated cleansers; use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun; antipruritics, including antihistamines.
- History of hypersensitivity or allergy to clindamycin phosphate, benzoyl peroxide, and /or any ingredient in the study medication.
- Females who are pregnant, breastfeeding, intending to become pregnant during the study, or who do not agree to use an acceptable form of birth control during the study.
- Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise the subject's ability to comply with study requirements.
- Any clinically significant condition or situation other than acne vulgaris that would interfere with the study evaluations or optimal participation.
- Use of any investigational drugs within 30 days prior to visit 1/day 1.
- Participation in any other clinical study in the 30 days prior to signing the informed consent form.
- Previous participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
|
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
|
ACTIVE_COMPARATOR: Acanya® Gel, 1.2%/2.5%
Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
|
Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
|
PLACEBO_COMPARATOR: Vehicle of test product
Vehicle of test product (Taro Pharmaceuticals Inc.)
|
Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean percent change in inflammatory lesion counts.
Time Frame: 12 weeks
|
Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.
|
12 weeks
|
Mean percent change in non-inflammatory lesion counts.
Time Frame: 12 weeks
|
Mean percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response of "success".
Time Frame: 12 weeks
|
The proportion of subjects at week 12 with a clinical response of "success" is defined as an Investigators Global Assessment score that is at least 2 grades less than the baseline assessment.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (ACTUAL)
September 1, 2013
Study Completion (ACTUAL)
December 1, 2013
Study Registration Dates
First Submitted
January 14, 2013
First Submitted That Met QC Criteria
January 15, 2013
First Posted (ESTIMATE)
January 16, 2013
Study Record Updates
Last Update Posted (ACTUAL)
May 5, 2017
Last Update Submitted That Met QC Criteria
May 3, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Dermatologic Agents
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
- Benzoyl Peroxide
Other Study ID Numbers
- CLBG 1210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Nexgen Dermatologics, Inc.Unknown
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
-
Watson Laboratories, Inc.Completed
-
Zydus Lifesciences LimitedCompletedAcne VulgarisUnited States, India
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
Zeichner, Joshua, M.D.UnknownAcne VulgarisUnited States
-
Taro Pharmaceuticals USACompleted
-
Zeichner, Joshua, M.D.Unknown
-
Padagis LLCCompleted
-
Mahidol UniversityWithdrawnFoot Dermatoses | Benzoyl PeroxideThailand
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States